A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

by Thomas Decker, Friedrich Overkamp, Siegfried Rösel, Arnd Nusch, Thomas Göhler, Martin Indorf, Jörg Sahlmann, Tanja Trarbach
Published 2017-07-01